Present and future of 5-HT receptor agonists as antimigraine drugs

Clinical Neuropharmacology

Volumn 22, Issue 3, 1999, Pages 123-136

  Pauwels, Petrus J ^a   John, Gareth W ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

5 HT(1B 1D) receptors; Antimigraine drugs; Intrinsic activity; Migraine; Partial agonist; Tryptamine derivatives

Indexed keywords

ALNIDITAN; ANTIMIGRAINE AGENT; AVITRIPTAN; DIHYDROERGOTAMINE; ELETRIPTAN; FROVATRIPTAN; NARATRIPTAN; RIZATRIPTAN; SEROTONIN; SEROTONIN AGONIST; SUMATRIPTAN; TRYPTAMINE DERIVATIVE; ZOLMITRIPTAN;

BINDING AFFINITY; BINDING SITE; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; MIGRAINE; PRIORITY JOURNAL; RECEPTOR INTRINSIC ACTIVITY; REVIEW; VASOCONSTRICTION;

ANIMALS; BLOOD PRESSURE; FORECASTING; HUMANS; MIGRAINE DISORDERS; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SUMATRIPTAN; VASCULAR RESISTANCE;

EID: 0033405243     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (137)

1. Goldstein ME, Chen TC. The epidemiology of disabling headache. Adv Neurol 1982;33:377-90.
2. Merikangas KR, Risch NJ, Merikangas JR, Weissman MM, Kidd KK. Migraine and depression: association and familial transmission. J Psychiatr Res 1988;22:119-29.
3. Stewart WF, Linet MS, Celentano DD. Migraine headaches and panic attacks. Psychosom Med 1989;51:559-69.
4. Marazziti D, Toni C, Pedri S, et al. Headache, panic disorder and depression: comorbidity or a spectrum? Neuropsychobiology 1995;31:125-9.
5. Kahn RS, Asnis GM, Wetzler S, Van Praag HM. Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder. Psychopharmacology 1988;96:360-4.
6. Brewerton TD, Murphy DL, Mueller EA, Jimerson DC. Induction of migraine-like headaches by the serotonin agonist m-chlorophenylpiperazine. Clin Pharmacol Ther 1988;43:605-9.
7. Gordon ML, Brown SL, Lipton RB, et al. Serotonergic parallels in migraine, depression, and anxiety. Nappi G, Bono G, Sandrini G. Martignoni E, Micieli G, eds. Headache and Depression: Serotonin Pathways as a Common Clue. New York: Raven Press, Ltd.; 1991:21-40.
8. Lance JW. 5-hydroxytryptamine and its role in migraine. Eur J Neurol 1991;31:279-81.
9. Raskin NHH. Serotonin receptors and headache. New Engl J Med 1991;325:353-4.
10. Sicuteri F, Testi A, Anselmi B. Biochemical investigations in headache: increase in the hydroxyindoleacetic excretion during migraine attacks. Int Arch Allergy Appl Immunol 1961;19:55-8.
11. Anthony M, Hinterberger H, Lance JW. The possible relationship of serotonin to the migraine syndrome. Friedman AP, ed. Research and Clinical Studies in Headache. New York: S. Karger; 1969:29-59.
12. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology 1960;10:107-11.
13. 1-like" receptors. Naunyn Schmiedebergs Arch Pharmacol 1986;333:198-204.
14. Humphrey PPA, Feniuk W. Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991;12:444-6.
15. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992;13:307-11.
16. -1B/D receptor agonist zolmitriptan (311C90): are brain stem sites a therapeutic target in migraine? Pain 1996;67:355-9.
17. Ferrari MD, Saxena PR. Clinical and experimental effects of sumatriptan in humans. Trends Pharmacol Sci 1993;14:129-34.
18. Tfelt-Hansen P, Lipton RB. Dihydroergotamine. Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press;1993;323-7.
19. Little PJ, Jennings GL, Shews H, Bobik A. Bioavailibility of dihydroergotamine in man. Br J Clin Pharmacol 1982;13:785-90.
20. 1B/1D receptor agonist, in models relevant to migraine [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1998;358(suppl 1):52.62.
21. 1B/1D receptor agonist [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1998;358(suppl 1):52.61.
22. 1B/1D receptors [abstract]. Naunyn Schmiedebergs Arch Pharmacol 1998;358(suppl 1)52.63.
23. Meng CQ. Migraine: current drug discovery trend. Curr Med Chem 1997;4:385-404.
24. Ferrari MD. Migraine. Lancet 1998;351:1043-51.
25. Humphrey PPA, Feniuk W, Marriott AS, Tanner RJN, Jackson MR, Tucker ML. Preclinical studies of the anti-migraine drug, sumatriptan. Eur Neurol 1991;31:282-90.
26. Kaube H, Hoskin KL, Goadsby PJ. Inhibition of sumatripan of central trigeminal neurons only after blood-brain barrier disruption. Br J Pharmacol 1993;109:788-92.
27. 3H] sumatripan binding in cat brain stem and spinal cord. Eur J Pharmacol 1995;280:175-8.
28. 1F receptor binding sites in the guinea pig brain: an autoradiographic study. Naunyn Schmiedebergs Arch Pharmacol 1995;352:263-75.
29. 1F receptors. Eur J Pharmacol 1996;295: 271-4.
30. Hoskin KL, Kaube H, Goadsby PJ. Sumatriptan can inhibit trigeminal afferents by an exclusively neural mechanism. Brain 1996; 119:1419-28.
31. 1 antagonists CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology 1995;34:255-61.
32. Humphrey PPA, Goadsby PJ. Controversies in headache. The mode of action of sumatriptan is vascular? A debate. Cephalalgia 1994;14:401-10.
33. Kaumann AJ, Parsons AA, Brown AM. Human arterial constrictor serotonin receptors. Cardiovasc Res 1993;27:2094-103.
34. 1D receptor subtypes mediating cerebral vasoconstriction. Cephalagia 1995;15 (suppl 14):99.
35. 1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia 1997;17:833-42.
36. 1F receptor activation-implications to migraine therapy. Abst Soc Neurosci 1996;22: 528.10.
37. 1F receptor agonist, in the neurogenic dural inflammation model of migraine pain. Abs Soc Neurosci 1996;22:528.11.
38. 1F receptor radioligand. Abs Soc Neurosci 1996;22:528.14.
39. 1F receptor. Abs Soc Neurosci 1996;22: 528.12.
40. 1F) receptor. Abs Soc Neurosci 1996;22:528.13.
41. 1F ligand LY334370 in guinea-pig brain sections and recombinant cell lines. Br J Pharmacol 1998; 124:283-90.
42. 3H] alniditan. Mol Pharmacol 1996;50:1567-80.
43. th International Headache Research Seminar: Headache Treatment, Trial Methodolog and New Drugs. Philadelphia: Lippincott-Raven Publishers; 1997: 279-85.
44. Saxena PR, Tfelt-Hansen P. Sumatriptan. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York: Raven Press; 1993:329-41.
45. 1D receptor agonists in the rabbit isolated saphenous vein. Br J Pharmacol 1996;119:35-42.
46. Hoyer D, Clarke DE, Fozard JR, et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994;46:157-203.
47. 1D receptor agonists in development for the acute treatment of migraine. In: Olesen J, Tfelt-Hanssen P, eds. Headache Treatment: Trial Methodology and New Drugs Philadelphia: Lippincott-Raven Publishers; 1997:229-41.
48. 1D receptor agonists. Exp Opin Invest Drugs 1996;5:581-93.
49. Valentin J-P, Bonnafous R, John GW. Contractile responses evoked by dihydroergotamine, naratriptan and sumatriptan in the canine isolated coronary artery. Fundam Clin Pharmacol 1998;12: 152-7.
50. 1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential. Eur J Pharmacol 1998;351:329-39.
51. 1B/1D-receptor ligand frovatriptan in human isolated basilar and coronary arteries. J Cardiovasc Pharmacol 1998;32: 220-4.
52. Maassen Van Den Brink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998;98:25-30.
53. 1B/D agonists: structure activity relationship and preclinical pharmacological distinctions. Curr Med Chem 1997;4:295-312.
54. Ferro A, Longmore J, Hill RG, Brown MJ. A comparison of the contractile effects of 5-hydroxytryptamine, sumatriptan and MK-462 on human coronary artery in vitro. Br J Clin Pharmacol 1995; 40:245-51.
55. 1D receptor agonists and human coronary artery reactivity in vitro: crossover comparisons of 5-HT and sumatriptan with rizatriptan and L-741,519. Br J Clin Pharmacol 1996;42: 431-41.
56. 1B receptor mRNA in pig coronary artery. Neurosci Res Commun 1998;23:45-53.
57. 1D-like receptor. Life Sci 1994;54:1671-80.
58. 1Dα receptor subtype expression in canine large coronary arteries and saphenous vein. Cardiovasc Res 1996;31:793-9.
59. 1B/1D receptor partial agonist, 311C90 (zolmitriptan). Br J Pharmacol 1997;121:157-64.
60. Raval P, Tilford NS, Smith SJ, et al. A comparison of the antagonist profile of SB 209509 (frovatriptan) and sumatriptan in human isolated basilar and coronary arteries. Br J Pharmacol 1996;119 (suppl)111.
61. Janssens WJ, Cools F, Proost F, Geyskens D, Verrelst J. Selectivity of alniditan towards isolated cerebral arteries. Cephalalgia 1997; 17:394.
62. Longmore J, Razzaque Z, Hargreaves R, et al. Rizatriptan selectively contracts human middle meningeal over coronary artery: comparison with sumatriptan. Cephalalgia 1997;17:388.
63. 1D antagonist properties. Cephalalgia 1997;17:404.
64. 1D receptor agonists, sumatriptan and naratriptan in anesthetized, open-chest pigs [abstract]. Cephalalgia 1995;15(suppl 14):9.
65. 1 receptor agonist [abstract]. Br J Pharmacol 1993;108: (suppl)260.
66. 1B/1D receptor agonist with anti-migraine activity. Naunyn Schmiedebergs Arch Pharmacol 1998;358:212-9.
67. Dixon R, Gillotin C, Gibbens M, Posner J, Peck RW. The pharmacokinetics and effects on blood presure of multiple doses of the novel anti-migraine drug zolmitriptan (311C90) in healthy volunteers. Br J Clin Pharmacol 1997;43:273-81.
68. 1B/D receptor agonists in the normotensive rat. Br J Pharmacol 1998;123: 205-14.
69. Le Grand B, Vié B, John GW. Effects of sumatriptan on coronary flow and left ventricular function in the isolated perfused guineapig heart. J Cardiovasc Pharmacol 1998;32:435-42.
70. Saxena PR. Cranial arteriovenous shunting: An in vivo animal model for migraine. In: Olesen J, Moskowitz MA, eds. Experimental Headache Models in Animals and Man. Philadelphia: Lippincott-Raven Publishers; 1995:189-198
71. Heyck H. Pathogenesis of migraine. Res Clin Stud Headache 1969; 2:1-28.
72. 1D receptor antagonist. Br J Pharmacol 1996;118: 85-92.
73. 1B/1D receptors. Eur J Pharmacol 1998;351:193-201.
74. 1B/1D receptor agonist, SB 209509 (VML251), and sumatriptan in dogs. J Cardiovasc Pharmacol 1997;30:136-141.
75. Lauritzen M. Cerebral blood flow in migraine and cortical spreading depression. Acta Neurol Scand 1987;76(suppl 113):9-40.
76. Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. J Neurosci 1993;13:1167-77.
77. Moskowitz MA, Cutrer FM, Lee WS, Waeber C, Limmroth V, Yu X. Drug discovery in migraine circa 1995. In: Olesen J, Moskowitz MA, eds. Experimental Headache Models in Animals and Man. Philadelphia: Lippincott-Raven Publishers; 1995:63-73.
78. Buzzi MG, Carter WB, Shimizu T, Heath H III, Moskowitz MA. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology 1991;30:1193-1200.
79. 1D receptor agonist 311C90. Headache 1994;34:394-9.
80. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in man and cats. Ann Neurol 1993;33:48-56.
81. Arvieu L, Mauborgne A, Bourgoin S, et al. Sumatriptan inhibits the release of CGRP and substance P from the rat spinal cord. NeuroReport 1996;7:1973-6.
82. 1 receptors in human neuronal and vascular tissues. In: Sandler M, Ferrari M, Harnett S, eds. Migraine Pharmacology and Genetics 1996;55-66. London: Chapman & Hall.
83. 1B antimigraine drug receptor in rat and human brain microvessels. Neuroscience 1998:86:1031-5.
84. May A, Shepheard SL, Knorr M, et al. Retinal plasma extravasation in animals but not in humans : implications for the pathophysiology of migraine. Brain 1998;121:1231-7.
85. 1B receptors. Mol Pharmacol 1996;49: 761-5.
86. Castro E, Romón T, Castillo J, del Olmo E, Pazos A, del Arco C. Identification and characterization of a new serotonergic recognition site with high affinity for 5-carboxamidotryptamine in mammalian brain. J Neurochem 1997;69:2123-31.
87. Lee WS, Moskowitz MA. Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638 exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res 1993;626:303-5.
88. Beattie DT, Connor HE. The pre-and postjunctional activity of CP-122,288, a conformationally restricted analogue of sumatriptan. Eur J Pharmacol 1995;276:271-6.
89. May A, Gijsman HJ, Wallnofer A, Jones R, Diener, Ferrari MD. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996;67: 375-8.
90. Shepheard SL, Williamson DJ. Hill RG, Hargreaves RJ. CP-122,288 is not "super potent" in inhibiting neurogenic dural vasodilatation in rats. Cephalalgia 1997;17:343.
91. Ryan RE, Elkind A, Goldstein J. Twenty-four-hour effectiveness of avitriptan in the acute treatment of migraine headaches. Headache 1997;37:245-8.
92. 1B/1D receptor agonists on neurogenic durai plasma extravasation and vasodilatation in anaesthetized rats. Neuropharmacology 1997;36:525-33.
93. 3H]-dihydroergotamine binding sites in the cat central nervous system: relevance to migraine. Ann Neurol 1991;29:91-4.
94. 3H] BRL43694. Cephalalgia 1995;15:11.
95. Goadsby PJ, Knight YE. Direct evidence for central sites of action of zolmitriptan (311C90): an autoradiographic study in cat. Cephalalgia 1997;17:153-8.
96. 3H] 311C90 binding sites in cat brain stem: implications for migraine treatment. Cephalalgia 1995;15(suppl 14):116.
97. Goadsby PJ. Studies of cerebrovascular pain pathways of relevance to migraine. In: Olesen J, Moskowitz MA, eds. Experimental Headache Models. Philadelphia: Lippincott-Raven Publishers, 1995:75-81.
98. Kaube H, Keay KA, Hoskin KL, Bandler R, Goadsby PJ. Expression of c-fos-like immunoreactivity in the caudal medulla and upper cervical spinal cord following stimulation of the superior sagittal sinus in the cat. Brain Res 1993;629:95-102.
99. Hoskin KL, Kaube H, Goadsby PJ. Central activation of the trigeminovascular pathway in the cat is inhibited by dihydroergotamine: a c-fos and electrophysiology study. Brain 1996;119:249-56.
100. 1B/1D) receptors. Br J Pharmacol 1997;122:918-22.
101. 1D receptors stably expressed in C6 glioma cells are coupled to calcium-dependent potassium channels. Br J Pharmacol 1997;122(suppl)253.
102. O'Shaughnessy CT, Connor HE, Feniuk W. Extracellular recordings of membrane potential from guinea-pig isolated trigeminal ganglion: lack of effect of sumatriptan. Cephalalgia 1993;13: 175-9.
103. Dahlof C, Diener HC, Goadsby PJ, et al. A multicentre, doubled-blind, placebo-controlled, dose-range finding study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. Headache 1995;35:292.
104. 1B/1D agonist zolmitritan (311C90, ZomigR). Cephalalgia 1997;17:849-54.
105. Ferrari MD, Gijsma H, Block GA, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-0462) in acute migraine. Presented at: American Association of study of rizatriptan of the Study of Headache; May 31-June 2, 1996; San Diego, CA.
106. Merck & Co. Annual Report 1994.
107. Cumberbatch MJ, Hill RG, Hargreaves RJ. Rizatriptan has central antinociceptive effects against durally evoked potentials. Eur J Pharmacol 1997;328:37-40.
108. 1D receptors. J Med Chem 1995;38:1799-810.
109. Hegerl U, Juckel G. Intensity dependence of auditory evoked potentials as an indicator of serotonergic neurotransmission: a new hypothesis. Biol Psychiatry 1993;33:173-87.
110. Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991;31:291-4.
111. 1B receptor polymorphism and clinical response to sumatriptan. Headache 1998;38:288-91.
112. 1F receptor gene: no evidence for involvement in response to sumatriptan in migraine patients. Am J Med Genet 1998;77:415-20.
113. Ottervanger JP, Van Witsen TB, Valkenburg HA, Grobbee DE, Stricker BHC. Adverse reactions attributed to sumatriptan. A post-marketing study in general practice. Eur J Clin Pharmacol 1994; 47:305-9.
114. Visser WH, Jaspers NMWH, de Vriend RHM, Ferrari MD. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 1996;16:554-9.
115. Ottervanger JP, Stricker BHC. Cardiovascular adverse reactions to sumatriptan. Cause for concern? CNS Drugs 1995;3:90-8.
116. Ferrari MD, Visser WH. Headache recurrence after subcutaneous sumatriptan. In: Sander M, Ferrari M, Harnett S, eds. Migraine: Pharmacology and Genetics. London: Chapman & Hall; 1996:82-93.
117. Ferrari MD, Terwindt GM, Visser WH, Reines SA. A placebo-controlled dose-ranging study of MK-462 versus sumatriptan in migraine. In: Rose FC, ed. New Advances in Headache Research. London: Smith Gordon & Co.; 1994:205-207.
118. 1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose range finding study. Neurology 1996;46,522-6.
119. 1 receptors in migraine pathophysiology and treatment. Eur J Neurology 1995;2:5-21.
120. 1D agonists: pharmacokinetic and pharmacodynamic aspects. In: Sandler M, Ferrari M, Harnett S, eds. Migraine: Pharmacology and Genetics. London: Chapman & Hall; 1996:94-108.
121. Orton DA, Richardson RJ. Ergotamine absorption and toxicity. Postgrad Med J 1982;58:6-11.
122. Rose A. Facing migraine in the new millenium. Inpharma 1997; 1101:3-4.
123. Prescott L. Naratriptan provides effective migraine control. Research & Development. Inpharma 1997;1084:9.
124. Goadsby PJ. A triptan too far? J Neurol Neurosurg Psych 1998;64: 143-7.
125. 1D receptor agonists as potential antimigraine agents. J Med Chem 1997;40:3501-3.
126. 1D agonists: potential new treatment for migraine without cardiovascular side effects. J Med Chem 1998;41:2180-3.
127. 1B/1D and novel receptors. Br J Pharmacol 1998;123:1561-70.
128. Fozard JR. 5-hydroxytrypamine and nitric oxide: the causal relationship between two endogenous precipitants of migraine. In: Sandler M, Ferrari M, Hamett S, eds. Migraine: Pharmacology and Genetics London: Chapman & Hall; 1996:167-74.
129. Fozard JR. The 5-hydroxytryptamine-nitric oxide connection: the key link in the initiation of migraine? Arch Int Pharmacodyn 1995; 329:111-9.
130. Edvinsson L, Mulder H, Goadsby PJ, Uddman R. Calcitonin generelated peptide and nitric oxide in the trigeminal ganglion: cerebral vasodilatation from trigeminal nerve stimulation involves mainly calcitonin gene-related peptide. J Auton Nerv Syst 1998;70:15-22.
131. 1 receptor activation. J Neurosci 1997;17:9545-53.
132. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990;28:183-7.
133. Gallai V, Sarchielli, Floridi A. Vasoactive peptide levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia 1995;15:384-90.
134. Deleu D, Hanssens Y, Worthing EA. Symptomatic and prophylactic treatment of migraine: A critical reappraisal. Clin Neuropharmacol 1998;21:267-79.
135. 1B receptors. Naunyn Schmiedebergs Arch Pharmacol 1996;353:144-56.
136. 1B/D receptor ligands: an answer from GTPγS binding studies with stably transfected C6-glial cell lines. Neuropharmacology 1997;36:499-512.
137. 1B receptor. Br J Pharmacol 1998;123:61-2.